Y-mAbs Therapeutics, Inc.
YMAB
$7.08
$0.233.36%
Weiss Ratings | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Good | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.66 | |||
Price History | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 14.01% | |||
30-Day Total Return | 31.84% | |||
60-Day Total Return | 41.88% | |||
90-Day Total Return | 28.73% | |||
Year to Date Total Return | 47.19% | |||
1-Year Total Return | 62.39% | |||
2-Year Total Return | -58.45% | |||
3-Year Total Return | -86.06% | |||
5-Year Total Return | -68.01% | |||
52-Week High % Change | -35.34% | |||
52-Week Low % Change | 162.22% | |||
Price | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $10.95 | |||
52-Week Low Price | $2.70 | |||
52-Week Low Price (Date) | Mar 24, 2023 | |||
52-Week High Price (Date) | May 15, 2023 | |||
Valuation | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | $308.84M | |||
Enterprise Value | 223.89M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.45 | |||
Earnings Per Share Growth | -85.37% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 3.32 | |||
Price/Book (Q) | 3.08 | |||
Enterprise Value/Revenue (TTM) | 2.41 | |||
Price | $7.08 | |||
Enterprise Value/EBITDA (TTM) | -32.69 | |||
Enterprise Value/EBIT | -29.26 | |||
Market Cap Category | Small Cap | |||
Dividends and Shares | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 43.621M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 646 885 8505 | |||
Address | 230 Park Avenue New York, NY 10169 | |||
Website | www.ymabs.com | |||
Country | United States | |||
Year Founded | 2015 | |||
Profitability | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -8.23% | |||
Profit Margin | -20.75% | |||
Management Effectiveness | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -3.51% | |||
Return on Equity | -- | |||
Income Statement | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | $92.90M | |||
Total Revenue (TTM) | $92.90M | |||
Revenue Per Share | $2.13 | |||
Gross Profit (TTM) | $81.51M | |||
EBITDA (TTM) | -$6.85M | |||
EBIT (TTM) | -$7.65M | |||
Net Income (TTM) | -$19.28M | |||
Net Income Avl. to Common (TTM) | -$19.28M | |||
Total Revenue Growth (Q YOY) | 63.15% | |||
Earnings Growth (Q YOY) | 71.86% | |||
EPS Diluted (TTM) | -$0.45 | |||
EPS Diluted Growth (Q YOY) | 71.43% | |||
Balance Sheet | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | $86.57M | |||
Cash Per Share (Q) | $1.98 | |||
Total Current Assets (Q) | $114.86M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | $100.15M | |||
Current Ratio (Q) | 5.266 | |||
Book Value Per Share (Q) | $2.30 | |||
Total Assets (Q) | $128.88M | |||
Total Current Liabilities (Q) | $21.81M | |||
Total Debt (Q) | $1.62M | |||
Total Liabilities (Q) | $28.73M | |||
Total Common Equity (Q) | $100.15M | |||
Cash Flow | YMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -- | |||
Cash from Financing (TTM) | $0.00 | |||
Net Change in Cash (TTM) | -$27.96M | |||
Levered Free Cash Flow (TTM) | -$8.71M | |||
Cash from Operations (TTM) | -$27.86M | |||